ENTITY
Eisai Co Ltd

Eisai Co Ltd (4523 JP)

114
Analysis
Health CareJapan
Eisai Co., Ltd. produces prescription drugs and medical equipment and sells mainly to sales agents and subsidiaries. Through its subsidiary, Sanko Junyaku, the Company produces and sells diagnostic drugs. Eisai also markets its products through related companies in the US, Europe, and Asia. The Company also manufactures and sells foods, livestock feeds, chemical, and agrochemicals.
more
bearishEisai Co Ltd
21 Nov 2024 09:30

Eisai Co Ltd (4523 JP): Mixed H1FY25 Performance; Guidance Reaffirmed; Leqembi Struggle Continues

​Eisai sees revenue growth but profit decline in H1FY25. The company reduced Leqembi guidance for FY25. Leqembi is expected to be approved in...

Logo
105 Views
Share
bullishEisai Co Ltd
03 Jul 2024 22:18

Eisai Co Ltd (4523 JP): New Competition Is Coming for Alzheimer’s Disease Drug; No Immediate Threat

​FDA approves Eli Lilly's Alzheimer's disease drug Kisunla. However, Eisai is not expected to face immediate competition and is expected to meet...

Logo
404 Views
Share
bullishEisai Co Ltd
16 May 2024 22:00

Eisai Co Ltd (4523 JP): Leqembi Is Gathering Momentum; Imminent Competition May Spoil the Party

​Eisai expects 13x jump in Leqembi revenue for FY25 to ¥56.5B, driven by progress in AD treatment pathways in U.S. and Japan, and China launch. A...

Logo
254 Views
Share
bearishEisai Co Ltd
09 Mar 2024 09:30

Eisai Co Ltd (4523 JP): Despite Sluggish Launch, Ambitious Long-Term Target Set for Leqembi

Eisai projects Leqembi revenue to reach ¥1.6T by FY33 with early and pre-clinical AD indications. As of January, Leqembi reached just 2K patients...

Logo
420 Views
Share
bearishEisai Co Ltd
03 Jan 2024 09:30

Eisai Co Ltd (4523 JP): Why Performance Reversal Is Not Expected in Near-Term

​Eisai shares are on downtrend due to disappointment with Alzheimer's drug. Top-selling drug Lenvima faces patent expiration in 2025. Eisai seeks...

Logo
661 Views
Share
x